OrganoTherapeutics and CASK Luxembourg asbl launch an initiative to develop patient-derived brain organoid models for CASK, a rare neurological disorder (Copy)
Esch-sur-Alzette, Luxembourg – [March 31, 2026]
About CASK Disorders
CASK-related disorders are rare X-linked neurodevelopmental diseases caused by mutations in the CASK gene. Primarily affecting children, they are generally associated with severe developmental delay, microcephaly, epilepsy, as well as significant motor and cognitive impairments. Due to the lack of disease-modifying treatments and the limited availability of relevant human models, there is a substantial unmet medical need in this field.
"For families affected by CASK, time is of the essence. This project brings hope by uniting scientific excellence with a strong commitment to openness and collaboration. We are proud to support an initiative that ensures the resulting knowledge and models will benefit the entire global CASK community." — Livia Nonorgues-Dahan, President of CASK Luxembourg asbl
OrganoTherapeutics, a pioneer in organoid-based disease models, and CASK Luxembourg asbl (an association founded by families of children with CASK) announce today the signing of a Memorandum of Understanding (MoU). This strategic partnership aims to combine OrganoTherapeutics' cutting-edge scientific expertise with the capabilities of CASK Luxembourg asbl and the CASK Coalition to optimize the development of new therapies.
"This MoU marks a key milestone in our mission to accelerate drug discovery through our human brain organoid platforms," says Dr. Schwamborn, CEO of OrganoTherapeutics. "Collaborating with CASK Luxembourg asbl allows us to strengthen our infrastructure and expand our impact within the Luxembourg healthcare ecosystem."
"This collaboration represents a decisive step toward creating robust and patient-relevant models in a field where such tools are sorely lacking. By combining advanced stem cell technology with open access for the community, we aim to create a resource that will not only advance our understanding of CASK biology but also accelerate the development of future therapeutic strategies." — Jens Schwamborn, CEO of OrganoTherapeutics
About OrganoTherapeutics
OrganoTherapeutics is a Luxembourg-based biotechnology company specializing in the development of patient-specific human cell models, with a particular focus on brain organoids. By integrating stem cell technologies, multi-omic profiling, and computational disease modeling, the company generates translationally relevant systems for disease research and drug discovery.
About the CASK Coalition
The CASK Coalition is an international alliance of non-profit organizations established in 2023 to coordinate research and support for families affected by CASK-related disorders.
To advance this project, CASK Luxembourg asbl has launched a fundraising campaign. We are counting on you!
Contact: Livia Nonorgues-DAHAN, President of CASK Luxembourg asbl
Email: caskluxembourg@outlook.com
Facebook: https://www.facebook.com/profile.php?id=61581012615477